Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages

Cara Therapeutics, Inc. (NASDAQ:CARA) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $27.84.

Separately, StockNews.com initiated coverage on shares of Cara Therapeutics in a research report on Friday. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CARA. FMR LLC grew its holdings in Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares in the last quarter. Curi RMB Capital LLC purchased a new position in Cara Therapeutics during the 4th quarter worth $277,000. Shay Capital LLC bought a new stake in shares of Cara Therapeutics in the 4th quarter worth $524,000. XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics in the third quarter valued at about $29,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Cara Therapeutics in the fourth quarter valued at about $953,000. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Stock Performance

Shares of Cara Therapeutics stock opened at $5.70 on Friday. The stock has a market capitalization of $26.07 million, a PE ratio of -0.27 and a beta of 0.50. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $11.52. The stock has a 50 day moving average price of $4.99 and a two-hundred day moving average price of $4.18.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.